FRANKFURT, Feb 26 (Reuters) – German drugmaker Boehringer Ingelheim said it hopes that drug candidate survodutide, co-developed to treat obesity and fatty liver with Zealand Pharma (ZELA.CO), opens new tab, could be launched in 2027 or 2028, contingent on favourable trial data.
Carinne Brouillon, in charge of Boehringer’s Human Pharma unit, told Reuters on Monday it was not yet clear in which one of the two targeted indications the drug would first be launched.